Prenetics Global Ltd is a company principally engaged in the provision of diagnostic and preventive products and services. The Company operates its business through two segments. The Diagnostics segment is mainly engaged in the sale of precision oncology testing services. The Prevention segment is mainly engaged in the design and sale of genetics testing, including update services, and stool-based deoxyribonucleic acid (DNA) tests for early colorectal cancer screening. The Company's products and services include CircleDNA, ACTOnco, ACTHRD and other products. The in-house developed consumer genetic testing product, CircleDNA, offers comprehensive DNA tests capitalizing on in-house developed testing algorithm. ACTOnco is a comprehensive cancer test used to guide treatment selection for major solid tumors. ACTHRD is a test for the homologous recombination deficiency status of cancer patients. The Company is also engaged in consumer health products by a new health and wellness brand IM8.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 324.92% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 92.39M.
Undervalued
The company’s latest PE is -6.31, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 1.76M shares, decreasing 30.62% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.